<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371176</url>
  </required_header>
  <id_info>
    <org_study_id>ORD-NIMH-20061</org_study_id>
    <nct_id>NCT00371176</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD</brief_title>
  <official_title>A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this project is to examine whether administration of D-Cycloserine (DCS),
      a partial N-methyl-D-aspartate (NMDA) receptor agonist that has been shown to facilitate fear
      extinction, enhances the therapeutic benefit of exposure-based cognitive behavioral therapy
      (CBT) in OEF/OIF veterans with PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      War-zone-related posttraumatic stress disorder (PTSD) is a major psychiatric disorder that
      includes specific disabling symptoms and impairments that interfere with a soldier's ability
      to do his or her job. There is strong evidence for cognitive behavior therapy (CBT) in
      treating PTSD in civilians, which suggests a prescription for returning veterans, but
      approximately 40% of patients retain a PTSD diagnosis (e.g., Foa et al., 1999) and drop-out
      rates are ~25%. It is imperative to develop novel evidence-based early interventions that are
      more acceptable to recent veterans and less draining of treatment resources. If CBT can be
      shortened and its efficacy boosted by cognitive enhancers then it is more likely that
      soldiers will get the most efficacious treatments for acute stress and PTSD. Our aim is to
      develop a program that is brief and effective, but will have long-term benefits for veterans
      by virtue of its greater amenability to self-management and treatment adherence beyond the
      therapy context.

      This study is a randomized, controlled, double-blind treatment trial comparing CBT plus DCS
      to CBT plus placebo. Participants will be 68 OEF/OIF veterans with PTSD randomly assigned to
      CBT plus DCS or CBT plus placebo. Procedures to screen subjects prior to randomization
      include a detailed phone screen, administration and collection of questionnaires, a medical
      assessment, and two baseline structured clinical interviews. Following randomization, both
      groups will receive the identical 6 session exposure-based CBT protocol. The DCS-augmented
      group will receive 50 mg of DCS 30 minutes prior to the four CBT sessions involving imaginal
      exposure, whereas the placebo-augmented group will receive a placebo pill prior to these
      sessions. Assessment interviews conducted by independent evaluators will occur at
      pre-treatment, post-treatment, and at 3, and 6-month follow-up. Self-report measures will
      also be administered at screening, throughout the 6 weeks of treatment, and at 3- and 6-
      month follow up.

      Comparison(s): OEF/OIF veterans with PTSD treated with CBT plus DCS, compared to OEF/OIF
      veterans with PTSD treated with CBT plus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale-IV</measure>
    <time_frame>Pre Intervention</time_frame>
    <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale-IV</measure>
    <time_frame>Post Intervention</time_frame>
    <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale-IV</measure>
    <time_frame>3 month follow-up</time_frame>
    <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale-IV</measure>
    <time_frame>6 month follow-up</time_frame>
    <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist</measure>
    <time_frame>Pre Intervention</time_frame>
    <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist</measure>
    <time_frame>Post intervention</time_frame>
    <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist</measure>
    <time_frame>3 month follow-up</time_frame>
    <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist</measure>
    <time_frame>6 month follow-up</time_frame>
    <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>Pre intervention</time_frame>
    <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>Post intervention</time_frame>
    <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>3 month follow-up</time_frame>
    <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>6 month follow-up</time_frame>
    <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Combat Disorders</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>D-Cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brief imaginal exposure therapy plus DCS pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Brief imaginal exposure therapy plus Placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure therapy</intervention_name>
    <description>A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist</description>
    <arm_group_label>D-Cycloserine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <description>A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.</description>
    <arm_group_label>D-Cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients 18 years of age or older who served in Operation Iraqi
             Freedom or Operation Enduring Freedom (OIF/OEF) and who have a primary diagnosis
             (designated by the patient as the most important source of distress of PTSD.

          -  Willingness and ability to comply with the requirements of the study protocol.

        Exclusion Criteria:

        A lifetime history of:

          -  bipolar disorder

          -  schizophrenia

          -  psychosis

          -  delusional disorders or obsessive-compulsive disorder

          -  organic brain syndrome

          -  cognitive dysfunction that could interfere with capacity to engage in therapy

          -  a history of substance or alcohol dependence (other than nicotine) in the last 6
             months or otherwise unable to commit to refraining from alcohol use during the acute
             period of study participation.

          -  Patients with significant suicidal ideation or who have enacted suicidal behaviors
             within 6 months prior to intake will be excluded from study participation and referred
             for appropriate services.

          -  Patients must be off concurrent psychotropic medication (e.g., antidepressants,
             anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized
             treatment.

          -  Serious medical illness or instability for which hospitalization may be likely within
             the next year.

          -  Patients with a current or past history of seizures

          -  Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted forms of contraception (e.g., intra uterine device, oral
             contraceptives, barrier devices, condoms and foam, or implanted progesterone rods
             stabilized for at least 3 months).

          -  Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing
             psychotherapy of any duration specifically targeting PTSD is excluded. General
             supportive therapy initiated &gt; 3 months prior is acceptable.

          -  Patients with seizures or ongoing severe cognitive impairment that compromised mental
             status.

          -  Patients receiving Isoniazid.

          -  Patients unable to understand study procedures and participate in the informed consent
             process.

          -  Patients with a history of renal insufficiency (creatinine clearance less than 50
             mL/min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett T. Litz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Boston Health Care System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012 Sep;46(9):1184-90. doi: 10.1016/j.jpsychires.2012.05.006. Epub 2012 Jun 12.</citation>
    <PMID>22694905</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2006</study_first_submitted>
  <study_first_submitted_qc>August 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <results_first_submitted>August 30, 2013</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2014</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive Behavior Therapy</keyword>
  <keyword>Cognitive enhancers</keyword>
  <keyword>Combat Disorders</keyword>
  <keyword>D-Cycloserine</keyword>
  <keyword>Stress Disorders, Post-Traumatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Combat Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was 2007 to 2011. Participants were recruited through VA clinician referrals and public advertising (e.g., flyers and radio ads).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>D-Cycloserine Plus Exposure</title>
          <description>Treatment entailed six 60-90 minute sessions. Session 1 focused on psychoeducation and building of rapport, sessions 2-5 of brief imaginal exposure therapy plus a 50 mg DCS pill 30 minutes prior to each session, and session 6 consisted of a review of treatment gains, discussion of relapse-prevention strategies, and termination.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Exposure</title>
          <description>Treatment entailed six 60-90 minute sessions. Session 1 focused on psychoeducation and building of rapport, sessions 2-5 of brief imaginal exposure therapy plus a placebo pill 30 minutes prior to each session, and session 6 consisted of a review of treatment gains, discussion of relapse-prevention strategies, and termination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-Cycloserine Plus Exposure</title>
          <description>Brief imaginal exposure therapy plus DCS pill</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Exposure</title>
          <description>Brief imaginal exposure therapy plus Placebo pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.77" spread="9.85"/>
                    <measurement group_id="B2" value="31.62" spread="9.10"/>
                    <measurement group_id="B3" value="32.19" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale-IV</title>
        <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
        <time_frame>Pre Intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale-IV</title>
          <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.85" spread="23.24"/>
                    <measurement group_id="O2" value="73.38" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist</title>
        <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
        <time_frame>Pre Intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist</title>
          <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.85" spread="8.76"/>
                    <measurement group_id="O2" value="39.00" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist</title>
        <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
        <time_frame>Post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist</title>
          <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.11" spread="21.09"/>
                    <measurement group_id="O2" value="24.18" spread="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale-IV</title>
        <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
        <time_frame>Post Intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale-IV</title>
          <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.33" spread="28.68"/>
                    <measurement group_id="O2" value="53.73" spread="26.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale-IV</title>
        <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
        <time_frame>3 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale-IV</title>
          <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.57" spread="32.17"/>
                    <measurement group_id="O2" value="58.20" spread="26.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale-IV</title>
        <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
        <time_frame>6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale-IV</title>
          <description>A 17-item, semi-structured interview of PTSD symptoms. The range of scores is 0-136, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.20" spread="32.17"/>
                    <measurement group_id="O2" value="55.50" spread="27.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist</title>
        <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
        <time_frame>3 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist</title>
          <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.29" spread="14.68"/>
                    <measurement group_id="O2" value="26.91" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist</title>
        <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
        <time_frame>6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist</title>
          <description>A 17-item, self-report measure of PTSD symptoms. The range of scores is 17-85, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.20" spread="13.16"/>
                    <measurement group_id="O2" value="27.25" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory</title>
        <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
        <time_frame>Pre intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory</title>
          <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.85" spread="15.31"/>
                    <measurement group_id="O2" value="21.48" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory</title>
        <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
        <time_frame>Post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory</title>
          <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.56" spread="16.25"/>
                    <measurement group_id="O2" value="14.18" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory</title>
        <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
        <time_frame>3 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory</title>
          <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.57" spread="14.43"/>
                    <measurement group_id="O2" value="13.90" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory</title>
        <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
        <time_frame>6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-Cycloserine Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus DCS pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Exposure</title>
            <description>Brief imaginal exposure therapy plus Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory</title>
          <description>A 21-item, self-report measure of depression symptoms. The range of scores is 0-63, with a higher value representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.25" spread="17.73"/>
                    <measurement group_id="O2" value="15.38" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-Cycloserine Plus Exposure</title>
          <description>Brief imaginal exposure therapy plus DCS pill</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Exposure</title>
          <description>Brief imaginal exposure therapy plus Placebo pill</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study experienced sustained recruitment difficulties, ultimately recruiting a smaller number of participants (N=26) than originally projected (N=68).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brett Litz</name_or_title>
      <organization>Boston VA Healthcare System</organization>
      <phone>857 364 4131</phone>
      <email>brett.litz@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

